My watch list  

231 Current news of Frost & Sullivan


You can refine your search further. Select from the filter options on the left to narrow down your results.

Global Pharmaceutical and Biotechnology Industry Boosts Confidence for Investors as the Market Expands

Companies are exploring new markets for innovative assets to add value to their pipeline, finds Frost & Sullivan


In recent years, the global pharmaceutical and biotechnology industry has outperformed other sectors in terms of stock market indices. The appeal of orphan drugs and systems that reduce the cost of healthcare will continue to attract investors to fund the industry.Analysis from Frost & Sullivan, ...


Orthobiologics Are the Future for Bone Healing

Innovations in biomaterials, graft design and other technologies have pushed these products to the forefront of the industry, says Frost & Sullivan


Autografts, the gold standard of bone grafts, have several limitations. As a result, new orthobiologics products are being developed for the benefit of patients as well as surgeons. Innovations in biomaterials and graft design have enabled these advanced products that mimic the natural human bone ...


Small Animal Imaging Crucial for Drug Development and Non-Invasive Identification of Diseases in Humans

Animal models are an efficient and cost-effective way to understand underlying mechanisms of several human conditions


The use of small animal models in basic and preclinical research is now an integral part of developing and testing new pharmaceutical drugs prior to commercialisation. Small animal imaging is an efficient and cost-effective research platform for the timely validation and commercialisation of ...


Drug Abuse Triggers Regulations to Push the Development of Tamper-Resistant Opioid Formulations for Pain Management

Targeted pain drugs that do not have side effects such as constipation and addiction have a huge market awaiting them, says Frost & Sullivan


The pain market is currently dominated by opioid analgesics, which have well-known side effects such as addiction and constipation. However, a $10 billion market exists for a company able to develop a novel, targeted pain therapy that excludes these side effects, indicating the huge opportunity ...


Recombinant and Prophylactic Treatments Boost Global Haemophilia Therapeutics Market

Haemophilia B segment will see high growth over the forecast period, finds Frost & Sullivan


Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to ...


Development and Commercialization of Antibacterial Drugs to Speed Up

The recently implemented GAIN Act is expected to lure companies back into R&D as well as attract new participants, finds Frost & Sullivan


The growing threat posed by multi-drug resistant gram-negative organisms (MDR-GNBs) is lending a sense of urgency to the development of antibacterial drugs worldwide. Upcoming regulatory reforms to lower R&D costs and provide incentives for new drug identification will create attractive ...


Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments

Close competition encourages established manufacturers to broaden the drug pipeline for targeted therapies, finds Frost & Sullivan


Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the market for its treatment. Further, popular drugs such as Almita and Avastin are nearing their patent expiry in 2015 and 2017 respectively. As such, the lung cancer therapeutics market offers ...


Healthcare is up for a Revolution with the Rise of Personal Genomic Tests

Frost & Sullivan finds that direct to consumer genomics, which were close to absent a decade ago, are currently thriving


As the era of personalized medicine dawns on healthcare, the need to understand an individual’s genetic information through genomic testing has risen. This emerging branch of medicine has given birth to multiple companies that provide genetic tests to help end users understand their genetic ...


European Hantavirus Diagnostics Market Tops US Market as a Result of Higher Disease Prevalence

Frost & Sullivan says existing competitors’ dominance of the niche market raises entry barriers


The European Hantavirus diagnostics market is growing at a compound annual growth rate (CAGR) of 5.8 percent, outperforming the U.S. market, which registered 3.7 percent. The European market is more robust primarily due to Hantavirus’ high prevalence rates in Russia, Scandinavia, Finland and ...


Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN

A US$150 billion healthcare market by 2017, says Frost & Sullivan


The dynamic healthcare landscape across the Asia-Pacific is expected to continue its strong growth momentum in areas of new entities, investments and products, with the accelerated evolution driven by innovation and opportunities afforded by ASEAN. Healthcare delivery across both primary care and ...


Page 1 From 24
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE